MRK:NYSEMerck & Company, Inc. Analysis

Merck (MRK) is trading at $119.07, essentially flat on the 20‑day and 50‑day SMAs (≈$119.2) and well above its 200‑day SMA of $98.4, confirming a bullish longer‑term bias. The RSI sits at 50.7, indicating neutral momentum, while the MACD histogram is negative and the signal line is bearish, suggesting short‑term pressure. Volume has been trending lower, and the stock is approaching the $124 resistance level with a support cushion near $112.7. Valuation metrics show a trailing P/E of 16.4 versus an industry average of 26.2, positioning MRK as a relative value play, yet a discounted cash‑flow model pins fair value around $66, implying the market is pricing in a premium. The dividend yield of 2.86% with a 45% payout ratio is supported by robust operating cash flow of $16.5 bn and a free cash flow of $11.9 bn, underscoring sustainability.
Recent material news adds catalyst potential: Merck’s $53‑per‑share cash acquisition of Terns Pharmaceuticals expands its oncology pipeline, and a positive Phase 3 result for the oral PCSK9 inhibitor enlicitide decanoate opens a new growth avenue. UBS lifted its price target to $145, and the consensus analyst median target sits at $135, reinforcing a buy consensus. Combined with a low beta of 0.48, moderate volatility (20.6% 30‑day), and a strong balance sheet, the outlook remains favorable for both income‑focused and growth‑oriented investors.